“We Treated Patients With Elite Nursing Care”: 106-Year-Old Alum Recalls Training She Received at Beth Israel School of Nursing

Belle Herman Weiss, retired nurse and oldest-known alum of Mount Sinai Phillips School of Nursing (formerly Beth Israel School of Nursing)

At 106 years old, Belle Herman Weiss, RN, is thought to be the oldest living alum from the Beth Israel School of Nursing, now the Mount Sinai Phillips School of Nursing (founded in 1902), and one of the oldest living nurses in New York. Belle, who retired years ago and lives in Westchester County, fondly recalls her time in nursing school, which she began at just 16 years old—during a time when harmful diseases were widespread and difficult to treat.

“I enjoyed all the experiences I had to go through in nursing school,” says Belle, who graduated in 1936. “I loved being with a lot of other young women and having a goal to achieve.”

A good student who loved studying medicine, Belle was fascinated with figuring out patients’ diagnoses, which she compares to being a detective solving medical mysteries. “My favorite subjects were anatomy and physiology. I had a good memory and I was able to remember all the bones and their function. I enjoyed being able to recite the different parts of the body and what they did,” she says.

However, the lack of penicillin and treatments for infectious diseases in the 1930s and 1940s made nursing a challenging—and potentially dangerous—career path. She remembers contracting a skin lesion from tuberculosis at a hospital she worked in, noting she was “very lucky” it did not spread to her chest.

“It was a very difficult time, and [we were] studying at a bad time,” says Belle of being a nursing student. But she says many nurses managed to avoid infections by donning the cloth masks, rubber gloves, and gowns available at the time, and especially, routinely washing their hands. “Luckily, most of us stayed pretty healthy,” she says.

After graduating from the Beth Israel School of Nursing, Belle received a public health degree from New York University, which she says aided her when she later worked for The Willard Parker Hospital in Manhattan, where many patients had polio and were cared for in iron lungs (large horizontal machines that patients would lie in, which stimulated breathing). Medical technology in those days, she explains, was far more rudimentary and cumbersome to work with. For example, intravenous (IV) therapy—a routine therapy administered by nurses today using prepackaged components and fluids—was rarely ordered in the 1930s and 1940s. When it was, nurses had to prepare all the separate components—a glass bottle of saline, a separate rubber stopper and tubing, and a metal needle—and it was quite a process.

How were IVs given in the 1940s and 1950s? 106-year-old nurse Belle Herman Weiss explains:

First you got the IV pole. Then you went into the utility room and you got a sterilized package that contained the container that you were going to put the saline in. Then you got the connection of tubing, and then you got the needle that went with it. Then you got the saline that you had to pour into it. You had to get this glass container connected to the rubber tubing and put a stopper on the tubing so it wouldn’t leak out. Then you filled the container with the saline from a big bottle and hung it on the pole. Then you let the air run out, and then you connected the needle. Before you called a physician to get them to put the IV in, you had to wrap two hot water bottles around the container to warm the fluid to room temperature. That’s how an IV was given.

She says hospitals also lacked antibiotics. In their absence, she says doctors would order “bodily irrigations”—treatments that involved washing out the nose, eyes, ears, throat, and other orifices, in the hope it would wash away disease.

“We used to have a saying, ‘If in doubt, wash it out,’” Belle says, adding that nurses also kept patients healthy by routinely bathing them “head to toe.”

After retiring from nursing at age 70, Belle worked in a doctor’s office as an administrator until she was 92. She put her nursing degree and training to good use over her long career—working at hospitals throughout New York City, Long Island, and Westchester County, as well as on an ambulance, where she helped transport patients with communicable diseases. She says she enjoyed taking care of people, and particularly loved her pediatric patients. One little girl who died from kidney disease stands out to her the most.

“I can still picture her sometimes, walking around her little crib, and reaching out her arms for me to pick her up,” she says. “Those memories stick with me.”

While Belle enjoyed a storied nursing career—in addition to getting married in 1943 and having three children, including a daughter who is an advanced practice nurse in Westchester County—the two-and-a-half years she spent training at the Beth Israel School of Nursing are still fresh in her memory. She remembers the intensive 12-hour work schedules, and still recalls the names of many fellow students and head nurses she trained with. The nursing program was very disciplined, she says, and helped her acquire valuable experience for her nursing career.

“I did get a very good training,” remembers Belle of the Beth Israel School of Nursing.  “We treated the patients with elite nursing care.”

Delivering the Future of Vaccines With mRNA Technology

From left to right, Peter Palese, PhD, Horace W. Goldsmith Professor of Medicine; Miriam Merad, MD, PhD, Mount Sinai Professor in Cancer Immunology; Özlem Türeci, MD, Chief Medical Officer of BioNTech; Uğur Şahin, MD, Chief Executive Officer of BioNTech; Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai

One of the great tools that helped turn the tide of the COVID-19 pandemic was the use of vaccines, which prevented millions of deaths and hospitalizations in the U.S. and around the world. Key vaccines were those based on messenger RNA (mRNA) technology, which provide information for the molecules that teach the cells in the body to generate proteins used by viruses or cancers, allowing the body’s immune system to recognize and fight off future infections or transformed cancer cells.

The Icahn School of Medicine at Mount Sinai honored the efforts of executives of German biotechnology firm BioNTech, which partnered with Pfizer to develop and make available one of the most widely used COVID-19 vaccines in the country, during its 54th Commencement on Thursday, May 11. Uğur Şahin, MD, Chief Executive Officer of BioNTech, and Özlem Türeci, MD, its Chief Medical Officer, received honorary Doctor of Science degrees.

Research into mRNA technology for vaccines goes back to the 1990s, and has grown in leaps and bounds since, said Dr. Türeci in a guest lecture hosted by the Marc and Jennifer Lipschultz Precision Immunology Institute, held separately from the Commencement.

The COVID-19 pandemic provided an opportunity for the technology to be adapted at a large scale, and the momentum gained and lessons learned was only the starting point to pave the way for greater heights for the development of mRNA vaccines, she said.

In this Q&A, Drs. Şahin and Türeci spoke about what the future of mRNA vaccines could look like.

After two years of COVID-19 vaccines:

  • An estimated 18 million hospitalizations were prevented
  • More than 3 million deaths were avoided
    Source: New York City-based foundation The Commonwealth Fund

Percentage vaccinated in United States by manufacturer:

  • Pfizer/BioNTech: 60%
  • Moderna: 37%
  • Johnson & Johnson: 3%
    Source: Centers for Disease Control and Prevention

What are some active areas of research in which mRNA technology is being worked on?

Dr. Şahin: There are investigational cancer vaccines in which mRNA technology is being used to deliver instructions to generate antibodies or cytokines. This technology can theoretically be used to deliver any bioactive molecule.

Our focus at the moment is the development of cancer vaccines, and one special application of cancer vaccines we’re working on is the so-called “personalized cancer vaccines.” mRNA technology is particularly well suited to deliver a vaccine that consists of mutations of the tumor identified from the patient.

Dr. Türeci presenting to members of the Marc and Jennifer Lipschultz Precision Immunology Institute.

What is it about mRNA technology that makes it so well suited for cancer vaccines?

Dr. Türeci: We have been interested in cancer vaccines all along, and tried different technologies, and mRNA is the delivery technology that comes with its own edge. Its immunogenicity is very versatile and its transience has the potential to lead to a favorable safety profile. These characteristics are the reasons why we chose mRNA to deliver cancer antigens.

Any solid cancer could be appropriate for application. We have ongoing clinical trials in melanoma, head-and-neck cancer, pancreatic cancer, and non-small cell lung cancer.

Beyond cancer vaccines, we believe any bioactive cancer immunotherapy that is based on protein could be delivered by mRNA.

What about non-cancer diseases? Is mRNA technology suitable there?

Dr. Türeci: There are other areas, such as infectious diseases, in which mRNA could have an advantage. As long as you have the right protein structure to stimulate an immune response, you can theoretically also use mRNA here.

There are clinical trials in infectious diseases: COVID-19, for example, but also malaria or shingles.

What are some current limitations of mRNA technology? And how are researchers working to overcome those?

Dr. Türeci: We are very far advanced in the delivery component of the technology, and these advancements have made COVID-19 vaccines, as well as cancer vaccines in clinical testing, feasible. However, if you want to target specific organs, you need specialized, targeted delivery technologies.

For example, if you want to address something in the brain, you need a delivery technology that brings the mRNA into the brain. There may be monogenetic diseases in which the sample protein is deficient in the organ, and so limits how the mRNA can be expressed there.

So the lipid nanoparticle used to contain the COVID-19 vaccine, for example, might not be applicable for any other organs?

Dr. Türeci: This delivery technology was specifically designed and developed to deliver mRNA to the lymphatic system. If the mRNA needs to be delivered to different organs, it required new formulation.

When the public first became aware of mRNA technology through COVID-19 vaccines, there was skepticism. Do you envision similar skepticism as new mRNA vaccines roll out, and if so, how can we dispel such skepticism?

Dr. Türeci: Skepticism can only be addressed by transparent communication, through the disclosure of data, and proper education. I think there is a zeitgeist of skepticism. That skepticism isn’t necessarily specific to mRNA technology. But once they start to understand the mechanisms behind the technology, and the rationale of why we’re working on it, we can start to dispel it.

Do you foresee mRNA technology to grow exponentially into the future?

Dr. Şahin: Yes, mRNA vaccines could be really big, but it will happen slowly. It will take a few more years, but we are starting to see really promising candidates using this technology.

Valentin Fuster, MD, PhD, at Commencement: In Pursuit of Progress

Valentin Fuster, MD, PhD, at Commencement: In Pursuit of Progress

Valentin Fuster, MD, PhD, President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, giving the Commencement address

Commencements are not only about graduating students being hooded and receiving their degrees, or outstanding individuals being recognized with honorary degrees, but also opportunities for wisdom to be passed down.

At the 54th Commencement of the Icahn School of Medicine at Mount Sinai, held at David Geffen Hall at Lincoln Center on Thursday, May 11, Valentin Fuster, MD, PhD, President of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, had the honor of bestowing wisdom upon a new cohort of physicians and researchers.

“I have the awesome responsibility of providing you with wise and inspiring words, but with the comfort that you might not retain them for more than 24 hours,” began Dr. Fuster with a chuckle. But beyond the humor, Dr. Fuster called on graduates and all present in the hall to reflect on the concept of progress, especially in medicine.

What Does It Mean to Progress?

Society has moved through time, but we can’t take progress for granted, said Dr. Fuster.

At present, and sadly not new in the history of humanity, the concept of progress appears to be challenged, he said. One, by an ongoing abandonment of traditional ethical and moral values, ​​and two, by radical groups threatening one of the most basic principles of human dignity, which is the right to live.

New perspectives of progress can only be advanced by youth with innovative training, and the graduating class at Icahn Mount Sinai represents a group key to that goal, Dr. Fuster noted.

Challenges to Progress

Scientific innovations have forged ahead at a rapid pace, and have created gaps—between digital and cognitive creativity, and between treating disease and preventing it.

In the first category, Dr. Fuster spoke of acceptable uses of recent technologies, such as the artificial intelligence tool ChatGPT, for preparing research manuscripts. However, the definition of acceptable uses should be questioned by the younger generation, he said. “Young people—you—are generally those with the highest exposure to digital technologies, and as such you are uniquely equipped for positive decision-making.”

Furthermore, while advanced technologies have become part of daily lives, clinicians need to realize that the digitization of body data can only be useful to the well-being of the patient when integrated thoroughly with a complete clinical and social history and physical examination—a reality that is being diluted in medical educational systems that are mainly focused on digital technology, Dr. Fuster said.

In the latter category, there remains a gap in thinking about where the line between treatment and prevention should lie. Experts have agreed on the importance of prevention, not just treatment, but there remain questions about when medical practitioners should intervene, Dr. Fuster said, exhorting the young graduates to continue contributing toward prevention efforts.

Contributing to Progress

Being an active participant toward progress can be fulfilling, but the journey will be fraught, said Dr. Fuster. There are three principles that can help during dark moments, he noted.

Resilience is key, as the road to personal fulfillment is long and often marked by frustration. Mentorship is next, as people often spend excessive energy pursuing ambitions before they are ready and tutors can help discover talent. The last is to give back to society, as generosity and empathy are always the basis of happiness.

Finally, Dr. Fuster called on the graduates to live in the moment. “In this special and unique day, please stop your clock and celebrate your achievement,” he said. “And turn the clock back to give thanks to all of those who helped you on this journey, in a sense, to make you ready to engage in progress.”

The honor of delivering the Commencement address is reserved for individuals who have made a big impact in the health and sciences field. Dr. Fuster has a long and illustrious career as a physician and researcher, and in recognition of his achievements, he was conferred an honorary Doctor of Science degree at the 54th Commencement. Here’s a look at his storied career over the decades:

1974-1982

Professorships, including in Medicine and Cardiovascular Diseases, and Pediatrics, at Mayo Medical School, Rochester, Minnesota

1982-1991

Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine

1991-1994

Mallinckrodt Professor of Medicine, Harvard Medical School, Boston

1994

Dean for Academic Affairs, Mount Sinai School of Medicine

1994-1997

Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine

1997-present

Richard Gorlin, MD/Heart Research Foundation Professor of Cardiology, Mount Sinai School of Medicine/Icahn School of Medicine at Mount Sinai

2002-present

Director, the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, The Mount Sinai Hospital

2006-2022

Founding Director, Mount Sinai Heart

2007-2009

Scientific Director, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain

2009-present

General Director, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain

2011-present

Physician-in-Chief, The Mount Sinai Hospital

2023-present

President, Mount Sinai Heart

Through work with Mount Sinai Heart, Dr. Fuster has also led initiatives and programs that have had a global impact.

Hypertension management in rural Kenya: Using a multidisciplinary approach to address the challenge of linking and retaining hypertensive individuals to a hypertension-management program, community health workers use a behavioral communication strategy and smartphone-based tools to reduce blood pressure and manage their health.

Sesame Street education project: In 2006, Dr. Fuster joined as an advisor for Sesame Workshop’s Healthy Habits for Life initiative, launched in 2005 to promote healthy lifestyles and diet among young children. In 2012, he collaborated on Sesame Workshop’s Global Health Initiative, and helped create a mini-series Barrio Sésamo: Monstruos Supersanos, or Super Healthy Monsters, which aired on Spain’s co-production of Sesame Street. Segments have since been incorporated into local versions of Sesame Street in Colombia, Germany, Netherlands, United States, and other countries.

Did you know: Dr. Fuster has a Muppet, named Dr. Valentin Ruster, modeled after him? The Muppet doctor is featured in Super Healthy Monsters, and he teaches fellow Muppets about the heart, and even hosts a game show about balanced diets with Cookie Monster as a contestant.

Polypill initiative: Mount Sinai Heart launched a program to combine aspirin, a statin, and an angiotensin-converting enzyme inhibitor into one pill to prevent heart disease. The program was not only launched in the United States, but made available to developing nations, with accompanying studies to determine whether the polypill is effective in reducing cardiovascular disease and improves adherence and accessibility to health care.

Cardiovascular disease prevention in children worldwide project: Dr. Fuster is pursuing a project that helps children acquire a healthy lifestyle and sustain it long-term through early education and intervention, preventing cardiovascular and other diseases later on in life. This project, presently reaching about 50,000 children worldwide, is rooted in the understanding that given greater brain plasticity in early years of life, what is learned and experienced in those ages will be enduring.

A Historic Commencement to Remember

Members of the pioneer classes of Mount Sinai medical school attending the 54th Commencement.

The Icahn School of Medicine at Mount Sinai celebrated its 54th graduating class on Thursday, May 11. A total of 172 degrees were conferred that day, ushering in a new generation of clinicians and researchers. However, the Commencement ceremony also celebrated another historic milestone:

“In attendance today are distinguished alumni who have had long and highly productive careers,” said Kenneth L. Davis, MD, Chief Executive Officer of the Mount Sinai Health System. “They are members of our first few graduating classes, from 1970, ’71, ’72, and my class, 1973. Together, they are celebrating the 50th anniversary of their graduation.”

One distinguished alumni who joined the Icahn Mount Sinai faculty on stage was Jeffery Flier, MD, Class of 1972, who had helped organize events celebrating this milestone. Events in the week leading up to Commencement included the 2023 Alumni Reunion Awards Ceremony Dinner at the New York Academy of Medicine, and a 50th milestone anniversary podcast, which interviewed members of the pioneer class.

“I would frequently tell people, ‘Don’t overthink what your career is going to be,’” Dr. Flier said in the podcast. As advice to recent graduates and future medical students, Dr. Flier noted that many people have many different careers during the course of their medical life, and one can’t predict what their opportunities are going to be. “Look for what you think will give you the greatest pleasure and opportunity that’s facing you right now,” he said.

Throughout the careers of these alumni, they have pushed the frontiers of medicine and science. Hover to read about where some of these outstanding individuals are today:

Ernst Schaefer, MD, class of 1972

Founder and Chief Medical Officer of Boston Heart Diagnostics.

Arthur Frank, MD, PhD, class of 1972

Professor of Public Health and Chair Emeritus of the Department of Environmental and Occupational Health, Drexel University’s School of Public Health, Philadelphia.

Jeffrey Flier, MD, class of 1972

Caroline Shields Walker Professor of Medicine, Harvard Medical School; former Dean of the Faculty of Medicine at Harvard University.

Naomi Luban, MD, class of 1972

Chair of the Institutional Review Board in the Office of Human Subjects Protection at Children’s National Hospital, Washington, D.C.

Curious how Icahn Mount Sinai has evolved over the years? From its first class to the present, the medical school has pushed itself to higher heights, reinventing itself many times over. Here’s a timeline of Icahn Mount Sinai through the decades.

1963

The New York State Board of Regents granted a charter to The Mount Sinai Hospital to create The Mount Sinai Hospital School of Medicine, permitting the school to grant MD and PhD degrees. A separate but overlapping Board of Trustees for the School was created.

1964

Charter amended to change name to Mount Sinai School of Medicine.

1967

Affiliated with City University of New York, name changed to Mount Sinai School of Medicine of City University of New York. First Faculty Assembly held, with approximately 1,200 faculty members.

1968

First students arrive: a first-year class with 36 students, including four women; a third-year class with 23 students; and 19 students in the Graduate School. Basic Science building on 102nd Street was opened.

1970

The first class of Mount Sinai School of Medicine graduated, with 23 students.

1972

First commencement of graduates who had spent all four years at Mount Sinai School of Medicine.

1973

First classes were held in the Annenberg Building.

1982

Department of Geriatrics and Adult Development created—a first in a U.S. medical school.

1984

Aron Residence Hall opened for medical students.

1987

Humanities and Medicine Program established to attract liberal arts students to careers in medicine

1989

Master of Science Degree in Community Medicine added, later changed to Master in Public Health.

1993

Mount Sinai School of Medicine, for the first time, graduated more women than men; a first in New York State.

1995

The Mount Sinai School of Medicine Consortium for Graduate Medical Education was established.

1996

East Building (now Icahn Medical Institute) opened.

1999

Affiliated with New York University, name changed to Mount Sinai School of Medicine of New York University.

2001

Institute for Medical Education established.

2003

Master of Science in Clinical Research added.

2005

Mount Sinai School of Medicine added new offerings, including Post-Baccalaureate Research Education Program, and Master of Science in Genetic Counseling.

2010

The Middle States Commission granted the School initial accreditation to be a free-standing accredited body and to grant its own degrees. Name changed to Mount Sinai School of Medicine.

1998

First White Coat Ceremony for first-year medical students.

2013

Name changed to Icahn School of Medicine at Mount Sinai in honor of trustee Carl Icahn. Mount Sinai Health System is announced, comprising Icahn Mount Sinai and seven affiliated hospitals. The medical school also announced an affiliation with Rensselaer Polytechnic Institute to collaborate on educational programs, research, and development of new diagnostic tools and treatments.

2015

The Tisch Cancer Institute at Icahn Mount Sinai was named a National Cancer Institute-designated cancer center.

2016

Icahn Mount Sinai and Stony Brook University on Long Island announced a partnership to develop joint graduate and medical educational programs.

2019

Master of Health Administration program added.

Voices From the Class of 2023 at Icahn Mount Sinai’s Commencement

Nicholas Athayde-Rizzaro, MD

Next step: psychiatry residency at Mount Sinai

I was part of the Primary Care scholars program, and the amazing thing about it is, from Year 1, you get exposure to clinics serving folks who are underprivileged and who can’t afford to go to bigger hospitals. That’s exactly what I wanted to get out of medical school. My family and, most importantly, my husband had been my pillars of support. He certainly went through medical school with me, and I could not have done this without him.

Christopher Bellaire, MD

Next step: orthopedic surgery residency at Georgetown University, Washington, D.C.

Even before I started at Mount Sinai, Valerie Parkas, MD, Senior Associate Dean of Admissions, Recruitment, and Alumni Affairs, and David Muller, MD, Dean for Medical Education, had helped me out a lot. They spearheaded a new program for military veterans interested in medicine, and created a one-of-a-kind program for veterans going into medical school. I’m just forever grateful for their leadership and advocacy for veterans in medicine.

Alexandra Capellini, MD

Next step: medicine/pediatrics residency at University of Michigan

My classmates are some of the most motivated, driven people to be around, and it’s made the whole journey exciting. It’s been quite a transformative journey. We started out as first-year med students, very eager and curious, and over the last five years, I really had a lot of mentors and classmates encouraging me to keep growing as a clinician and as a clinical researcher.

Steven Chen, MD, PhD

Next step: internal medicine residency at Weill Cornell Medical Center, New York City

I’m nervous, excited, happy—a whole mix of things. Very happy to be finally finishing my degree, but I’m nervous for what’s next, which is residency. I’m a little nervous for that, but excited to get started. When I came, I was a young 20-year-old. Since then, we’ve gone through a global pandemic. I feel like I’ve grown as a human, as a scientist, as a doctor, and I’m excited for the next part of my journey.

Christopher Guevara, PhD

Next step: business development associate at Mass General Brigham, Boston

One of the biggest moments that will stick with me is the PhD proposal, where you present your ideas, and getting your committee’s thumbs up. Like, “OK, this is what you’re going to be doing for the next couple of years.” It was awesome to have so many supportive people and being at the forefront of innovation.

Margaret Hung, PhD

Next step: postdoctoral fellow at Mount Sinai

This is one of the first times that it’s been just me and a microscope, finding out things for the first time, and to know something that no one else knows in the world for just a second, by yourself, is so incredible. That passion for discovery, the friends I’ve made here, and the contributions that I’ve made to Mount Sinai is something I’m going to carry with me forever.

James Johnson, MD

Next step: internal medicine residency at Mount Sinai

What I’ll miss about our class: it feels like we have such diversity, not only in demographics, but also in schools of thought and the ways people approach thinking about issues and tackling difficult cases. That kind of perspective variety makes us a really well-rounded group that it’s been an honor to be a part of.

David Kohler, MD

Next step: pediatrics residency at Mount Sinai

There were challenges during my time at Mount Sinai. I have a complex case of inflammatory bowel disease, and it was what informed my coming to medical school to begin with. I had five intestinal surgeries during the course of medical school, and had a bowel perforation, which was treated at the Mount Sinai Emergency Department. The support that I had from the faculty and administration was phenomenal.

Ryan Neff, MD, PhD

Next step: internal medicine residency at Mount Sinai

This has been such an incredible, long journey. I’ve been at the MD/PhD program at Mount Sinai for the last eight years. It feels like I’ve taught myself so many things about my own resiliency and learned about the resiliency and dedication of my classmates. It had been a difficult time; there had been so many unforeseen things. This Commencement is such a capstone on all that, and we’re moving into the next chapter where we really take all those lessons and put them into practice.

Kasopefoluwa (Sope) Oguntuyo, MD, PhD

Next step: internal medicine residency at Mount Sinai

At the beginning of the COVID-19 pandemic, I had the opportunity to repurpose some of the tools that I used during grad school to study SARS-CoV-2 entry as well as entry inhibition. During my clinical years, I had the opportunity to leverage my virology background to talk to patients about SARS-CoV-2 and vaccines. My time at Mount Sinai had been a beautiful blend of both conducting research and learning to care for patients.

Paloma Orozco Scott, MD

Next step: internal medicine residency at University of California, San Francisco

The question now is: who is going to shape me next? I am over the moon. I keep on telling myself that it feels like I just got into summer camp, but I know I’m going to be working really hard, and I really feel that every day is going to be so full. I’m going to be learning exactly what I want to be learning, in a community that I want to be learning in, and I have every confidence that I will be shaped into an excellent doctor.

Roosheel Patel, PhD

Next step: senior translational scientist at Tempus Labs, New York City

I think every day at Mount Sinai has been a journey, and I’m glad the last three years has culminated to this moment. I’m going to miss the friends and community. I’m from Texas, so when I moved here, it felt like I moved to a different country. But within a week or two, I found a group of friends who helped me get through the last three to four years.

Navigate with the arrows to learn more about the Class of 2023 and their time in medical school.

The class of 2023 graduated from the Icahn School of Medicine at Mount Sinai on Thursday, May 11, after a journey that was not only long, but marked by tribulation.

“You witnessed the strong moral character of our Mount Sinai physicians, nurses, and other medical professionals. You saw them put their lives on the line to battle COVID-19, to save lives,” said Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai, addressing graduating students and their families and friends, faculty, and trustees, at the Commencement ceremony.

“You witnessed our scientists, shortly after the onset of the pandemic, return to their laboratories to solve the riddles of the COVID-19 pandemic,” Dr. Charney said.

As guests gathered at David Geffen Hall at Lincoln Center to celebrate the new cohort of physicians and scientists embarking on the next step of their careers, none were more excited than the graduating students.

“We are the last class to graduate from Mount Sinai who all began medical school before the pandemic,” noted graduating student James Johnson, MD, who gave a speech on behalf of his class.

“Because of this, we all had other motivations to practice medicine—other primary drivers in our pursuit of this field,” Dr. Johnson said. “We still own those passions and hobbies we enjoyed at the start, and we can still channel them when the road ahead appears dark yet again.”

Click to read what some graduates had to say on what drew them to the profession and Icahn Mount Sinai:

Margaret Hung, PhD

What drew you to research and to Mount Sinai?

I fell in love with the vibrancy and community at Mount Sinai. It’s a world class hospital with incredible basic science and translational research, but what sets it apart from other high-ranking institutions was how down to earth my training area, department, and institute were. Mentors truly cared and were heavily invested in my success beyond what I could supply from the bench. That type of commitment provided me with a very well-rounded, foundational training as a scientist.

Was there a challenging moment during your time at Icahn Mount Sinai, and how did you overcome it?

Like many other researchers at Mount Sinai, the COVID-19 pandemic turned my research upside down. I was a third-year student and my work with mice on a skeletal muscle stem cell project had just started scaling up when the pandemic hit.

Unfortunately, I did not have the option to pivot to COVID-19 research for my thesis work. It felt like the floor had fallen out from under me. The enthusiasm and excitement I had gave way to severe anxiety from not knowing what would happen next, if I would be able to complete a project, or what my PhD would even look like.

In the months following our return to labs, when I had to restart my projects, everything felt slow and hopeless due to supply chain issues and lack of mice. With the support of my mentor, Robert Krauss, PhD, professor of Cell, Developmental and Regenerative Biology, my lab, and my colleagues, I was able to celebrate small victories as I slowly returned to full-scale experiments. I’m so grateful that I could find that excitement again and finish a dissertation that I could be proud of.

Kasopefoluwa (Sope) Oguntuyo, MD, PhD

What drew you to medicine and research and to Mount Sinai?

My experiences during my undergraduate and post-baccalaureate years drew me to medicine and research. I recognized that medicine represented the application of current knowledge to care for patients now and research represented the potential to generate knowledge to ultimately improve patient care in the future. I am excited to continue using my stethoscope to care for patients now and a pipette to work towards improving patient care.

Prior to my matriculation into the MD/PhD program, I was a National Institutes of Health scholar at the Post-baccalaureate Research Education Program at Mount Sinai. As a result, I had a glimpse into the unique community here, which included an incredibly passionate student body with varied interests, a collaborative and innovative research environment, and compassionate clinicians.

What three words would you use to describe your journey at Icahn Mount Sinai?

Creative—In my pre-clinical years, I took a short writing seminar called “Words to Live By.” We discussed pieces by published authors and workshopped our own pieces. I had the opportunity to read incredible pieces from my peers, which included chapters from novels, short stories, or poems. I have had the opportunity to receive feedback on several of my pieces and even published a few essays and poems.

Collaborative—Throughout my graduate years in the lab of Benhur Lee, MD, Professor of Microbiology, I’ve collaborated with various labs at Mount Sinai and other domestic and international labs. The SARS-CoV-2 work we did was a reflection of this collaborative spirit and we shipped out a ready-to-use system of Biosafety Level 2 (BSL2) viruses and cells to collaborators in Louisiana and Argentina and many other places to study SARS-CoV-2 entry biology and test entry inhibition.

Community—I’ve been a member of various communities during my time at Mount Sinai. These included organizations intended to foster community for students from backgrounds traditionally underrepresented in medicine or research, the Mount Sinai Climbing Club, and playing adult league soccer with my peers.

Nicholas Athayde-Rizzaro, MD

What drew you to medicine and Mount Sinai?

Growing up as a transgender person in Brazil was not easy. I suffered with institutional and societal exclusion, including being kicked out of high school and being unable to access health care simply for being queer.

While I had always dreamed of pursuing a career in medicine, my experiences of marginalization motivated me to become a physician who can create a safe, respectful, and welcoming environment not only for trans folks, but for all of those who come from vulnerable and underserved communities.

Not only was I accepted into Mount Sinai, I was also accepted to the Primary Care Scholars Program, which provided an opportunity to get longitudinal exposure to safety-net clinics throughout all four years of medical school. My acceptance to the program, coupled with Mount Sinai’s humanistic ethos, the diversity of New York City’s patient population, and my own personal story of coming back full circle to the place where I was born to pursue my dream of studying medicine made Icahn Mount Sinai the clear choice for me.

Can you recall a moment at Icahn Mount Sinai that has helped you grow?

During the height of the pandemic, students were not allowed to go into labs, which completely derailed my summer research project. I had to change directions, and I ended up designing a survey to assess what access to health care looked like for the trans community during the pandemic. This was a difficult undertaking since it was an independent research project and I had never built an entire project from scratch.

However, I had help from the Director of the Medical Student Research Office, Mary Rojas, PhD, who guided me along the way. I also never expected to get the amount of responses I did on my survey, and was profoundly grateful that so many participants trusted this project to make their voices heard. Not only did I push my limits and learn a lot, but I was also moved by the support I received from Dr. Rojas and by the engagement from the trans community.

Match Day 2023: A Message in a Bottle Launches a New Journey

As the 2023 class of medical school students from the Icahn School of Medicine at Mount Sinai filled the Guggenheim Pavilion on Friday, March 17, the air was abuzz with smiles and hugs from familiar faces. The hour drew closer to noon, and the fourth-year students, along with tens of thousands of their peers across the country, awaited the arrival of a message that would mark the next phase of their medical careers: their residency program matches on Match Day.

“This class will forever be in the history of Mount Sinai,” said Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai, addressing expectant attendees. The class arrived as first-year students and began their training during the thick of the COVID-19 pandemic in New York City.

“Adversity reveals character, and the way you handled the pandemic says a lot about who you are,” said Dr. Charney. “You did great. You’re going to find out in a minute or so that you matched to the best programs in the United States.”

Match Day celebrates the Main Residency Match, conducted by the National Resident Matching Program (NRMP). The program aligns the preferences of applicants with the preferences of residency programs at teaching hospitals across the nation through mathematical algorithms.

This year, Icahn Mount Sinai’s graduating MD class received their matches in a personalized bottle. They matched to many of the nation’s most competitive residency programs, spanning more than 22 specialties across the country.

Learn more about the numbers behind Match Day 2023 and celebrate these exceptional individuals with us.

Fourth-year MD students from Icahn School of Medicine at Mount Sinai received their residency matches in a personalized bottle on Match Day 2023

The 2023 Main Residency Match was the largest in NMRP’s 70-year history—with 42,952 applicants, 34,822 of whom matched to a first-year position (PGY-1)

With 81.1 percent of applicants for 2023 matched, it represents a 1 percent increase over the previous year

Mount Sinai Health System welcomes 512 new residents, who will arrive in July

The Health System’s new residents come from some of the top medical schools in the United States, including 55 Icahn Mount Sinai graduates

From Icahn Mount Sinai’s Class of 2023, comprising 137 students, 26.3 percent matched into primary care specialties, 23.4 percent matched into surgical specialties, and 40.9 percent matched into other specialties

In the other specialties, Icahn Mount Sinai’s graduating class had the most matches into psychiatry, with 8.8 percent. This was followed by anesthesiology and emergency medicine, both with 7.3 percent, and dermatology, with 5.1 percent

A record number of primary care positions were offered in the 2023 Main Residency Match. There were 571 more primary care positions than 2022, an increase of 3.2 percent over last year and an increase of 17 percent over the last five years. Primary care positions also were filled at a rate of 94.2 percent, which remained steady from last year

Pin It on Pinterest